Creditors Foreclose on Assets of SNDL’s Parallel

September 25, 2023 · Green Market Report

After the market closed on Friday, SNDL Inc. (NASDAQ: SNDL) told investors that it finally took steps regarding its SunStream joint venture and its underperforming Parallel cannabis assets.

The company’s joint venture Sunstream Bancorp launched SunStream USA with the expectation that Parallel will be restructured.

In March 2021, Sundial Growers Inc., now known as SNDL, formed SunStream Bancorp, a 50/50 joint venture with SAF Opportunities LP, a member of the SAF Group. SunStream Bancorp is the owner of $145 million of junior notes owned by Parallel that are in default. This exposes Sundial to the loss.

For years, Parallel has been tied up in a lawsuit with disgruntled investors over taking on too much debt ,among other things. However, despite Parallel defaulting on the debt, SunStream has continued to recognize the full value of the investment on its books.

Parallel Restructuring

SNDL said in its Friday statement that on Sept. 21, Talladega LP, a partnership wholly owned by affiliates of SunStream and creditors of Parallel, signed a strict foreclosure agreement with Parallel. As a result, CDXX TransCo LLC will foreclose on some of Parallel’s cannabis operations in Florida, Massachusetts, Texas, and Nevada that were pledged as collateral under Parallel’s existing debt instruments.

Once the foreclosure is closed, TransactionCo will own the operations in those states and have approximately $100 million of debt outstanding, of which $42 million will be held by Talladega. That represents a reduction of more than 80% from Parallel’s total outstanding debt.

TransactionCo’s post-closing capital structure should be supportable with a path to profitability, allowing it to take advantage of the growing cannabis market in the U.S.

SunStream USA is expected to own two-thirds of the equity interests of TransactionCo, while the remaining one-third is expected to be owned by the senior noteholders of Parallel’s existing senior secured notes

“The restructuring of nonperforming credit investments in SunStream is a notable opportunity to rebalance the risk-reward of SNDL’s existing investments,” Zach George, CEO of SNDL, said in the statement.

In the second quarter of 2023, Parallel‘s net revenue was $52 million or $208 million annualized.

Foreclosed Assets

SNDL listed the following items as the assets that have been foreclosed upon:

  • Florida: Parallel has 45 dispensaries that operate under the Surterra Brand, along with two cultivation facilities comprising more than 330,000 square feet.
  • Massachusetts: Parallel has three operating dispensaries under the New England Treatment Access brand and a 43,000-square-foot cultivation facility.
  • Texas: Parallel has two retail pick-up locations in Texas that operate under the brand Goodbled and a small cultivation facility.
  • Nevada: Parallel has a joint venture with Cookies and minor real estate assets.

Parallel’s History

Talladega initially provided Parallel with a $150 million loan on May 7, 2021, which was secured by a junior security interest on substantially all of Parallel’s assets, as well as a senior security interest on Parallel’s Massachusetts-based business. Parallel defaulted on the initial loan in September 2021.

Following the default, Talladega and the senior noteholders attempted to salvage the situation and explored selling the assets. During this time, Talladega and some of the senior noteholders gave Parallel a bridge loan of $78 million secured by a first-priority lien on substantially all of Parallel’s assets.

However, SNDL said that the marketing process did not result in a satisfactory outcome for Parallel’s senior creditors.  That’s when Parallel, SunStream (through Talladega), and the senior noteholders began looking at other options, including a strict foreclosure transaction.

As the talks continued, Talladega gave Parallel another $38 million in super-senior bridge financing between Dec. 7, 2022, and the signing of the foreclosure agreement to fund various restructuring costs and allow Parallel to continue its operations.

The Parallel Transaction is expected to close in the fourth quarter of 2023. (Full Story)

In category:Business
Next Post

Wholesale cannabis prices rise in key states, but downward pressure expected

Wholesale cannabis prices stabilized or rebounded in some key markets through the summer, but cultivators should brace for renewed downward pressure as the fall harvest boosts inventories through the end of the year, experts say. Chalk it up to simple…
Read
Previous Post

Widespread product recall upends Missouri’s cannabis industry

A widespread recall targeting tens of thousands of infused cannabis products in Missouri has led to millions of dollars in lost sales and inventory for retailers and manufacturers, according to industry sources and court documents obtained by MJBizDaily. At the same…
Read
Random Post

Jim Belushi Excited About Season 3 of 'Growing Belushi'

Jim Belushi can't wait for the Apr. 5 Season 3 premiere of Growing Belushi on Discovery+. The network planned for an earlier rollout in February, but then decided to wait until April - the month of the 4/20 stoner holiday. Season…
Read
Random Post

These Academics Went Public About Using Drugs

When drug policy researcher Jean-Sébastien Fallu saw a recent op-ed in the Atlantic argue that destigmatizing drug use has been “a profound mistake,” he was furious.  The piece said “cultural disapproval of harmful behavior can be a potent force for protecting public…
Read
Random Post

Measuring Light in the Garden

Nearly all life on Earth requires light to survive, and cannabis is no exception. While cultivators can certainly grow a plant with any common light source, cannabis plants will only thrive under specific spectrums and wavelengths that need to change…
Read
Random Post

Congress allows Washington DC medical cannabis reforms to become law

Medical cannabis is expected to be much more easily and widely available in Washington DC after a set of reforms that include lifting a cap on dispensaries and allowing patients to “self-certify” became law this week. Congress had until March 22 to interfere…
Read